Creo Medical Group’s (CREO) “House Stock” Rating Reiterated at Shore Capital Group

Shore Capital Group reaffirmed their house stock rating on shares of Creo Medical Group (LON:CREO) in a research report sent to investors on Thursday, Marketbeat Ratings reports. Shore Capital Group currently has a GBX 40 price target on the stock.

Creo Medical Group Trading Up 0.9%

LON:CREO opened at GBX 13.75 on Thursday. The company has a market cap of £66.80 million, a PE ratio of 13.75 and a beta of 1.62. Creo Medical Group has a 12 month low of GBX 9.52 and a 12 month high of GBX 18.50. The company has a 50 day simple moving average of GBX 13.74 and a two-hundred day simple moving average of GBX 13.30. The company has a current ratio of 3.22, a quick ratio of 2.19 and a debt-to-equity ratio of 8.20.

Creo Medical Group (LON:CREO) last issued its earnings results on Friday, May 22nd. The company reported GBX (0.04) earnings per share (EPS) for the quarter. The business had revenue of GBX 600 million for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. Research analysts forecast that Creo Medical Group will post -10.0800005 earnings per share for the current year.

Insider Transactions at Creo Medical Group

In related news, insider Richard John Rees acquired 6,250 shares of Creo Medical Group stock in a transaction on Wednesday, July 1st. The stock was acquired at an average price of GBX 14 per share, for a total transaction of £875. Also, insider Craig Jonathan Gulliford bought 6,250 shares of the stock in a transaction dated Wednesday, July 1st. The stock was bought at an average price of GBX 14 per share, for a total transaction of £875. Company insiders own 6.92% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.